Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | HPD | P32754 | 1/20 | 0.38 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690348 | 0.90 | BRD4 (0.51) | SMN1; SMN2NPC1RAB9AMAOBMAOA | |
| SCHEMBL16690430 | 0.82 | GRM5 (0.38) | MEN1KMT2ABRD4MAPK14CYP1A2 | |
| SCHEMBL18037164 | 0.82 | MAOB (0.40) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL18037163 | 0.80 | DGAT1 (0.41) | BRD4 | |
| SCHEMBL16690360 | 0.80 | BRD4 (0.41) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16690352 | 0.79 | BRD4 (0.35) | SMN1; SMN2BRD4MAPK14PTGER1MAPT | |
| SCHEMBL17744718 | 0.78 | PTGER1 (0.41) | MEN1KMT2ASMN1; SMN2RAB9ALMNA | |
| SCHEMBL16442812 | 0.75 | PTGER1 (0.41) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16385570 | 0.74 | MAPT (0.39) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16385265 | 0.73 | ATM (0.39) | SMN1; SMN2NPC1RAB9AHTTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2015064727-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | 住友化学株式会社 | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | TCOF1, TAOK2, CYC1 | MEN1 2116/4885KMT2A 1430/4885SMN1; SMN2 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.